vimarsana.com

Page 18 - திரிவேதி பள்ளி ஆஃப் உயிர் அறிவியல் இல் அசோகா பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Coronavirus variants with two specific mutations may evade antibodies, says virologist Shahid Jameel

Coronavirus | Variants with two specific mutations may evade antibodies, says virologist Shahid Jameel Updated: Updated: February 21, 2021 20:39 IST The spike protein of the coronavirus enables it to bind to the ACE2 receptor on host cells a process which studies have show to be crucial for the virus to enter the cells and cause infection. Share Article Shahid Jameel, Virologist, and Director, Trivedi School of Biosciences, Ashoka University   The spike protein of the coronavirus enables it to bind to the ACE2 receptor on host cells a process which studies have show to be crucial for the virus to enter the cells and cause infection.

India Covid-19 numbers plunge amid warnings of virus comeback

Covid killed 1,000 Indians a day Then hospitals fell silent as infections fell

Covid killed 1,000 Indians a day Then hospitals fell silent as infections fell
thenationalnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenationalnews.com Daily Mail and Mail on Sunday newspapers.

With two vaccines already approved, can placebos be used in trials?

Updated: February 14, 2021 14:46 IST From an ethical perspective, all persons in a control arm should at least receive the standard of care Share Article AAA Ensuing trial: For CovoVax, the drug regulator has allowed Serum Institute to use a placebo if participants on the placebo arm could be unblinded 60 days after the second dose upon their request and offered the candidate vaccine.   | Photo Credit: Bill Oxford From an ethical perspective, all persons in a control arm should at least receive the standard of care On February 3, 2021, the Subject Expert Committee of the Indian drug regulator approved Pune-based Serum Institute to conduct a phase-2/3 trial of CovoVax COVID-19 vaccine that was originally developed by Novavax Inc. headquartered in the U.S. Novavax’s vaccine was found to have over 89% efficacy in a phase-3 trial carried out in the U.K. In mid-January Dr. Reddy’s lab was allowed to carry out a phase-3 trial of Sputnik V vaccine. There are other vaccines wh

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.